We further assessed functional consequences of this upregulation for ex-vivo drug response and found that Tris12M-PG and Tris12U-PG were significantly more sensitive to BcR pathway inhibitors (e.g. ibrutinib, idelalisib) measured in an ex-vivo co-culture model of stroma- and CLL cells (Supplementary Fig. 9c). Here, BCR is linked to B-cell chronic lymphocytic leukemia.